iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: GlobeNewswire
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) announces today that it has entered into a collaboration agreement with AstralBio, Inc. (“AstralBio”) to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. Yesterday, iBio announced the closing of a $15 million private placement financing with ADAR1 Capital Management, Lynx1 Capital Management, Ikarian Capital and other instit
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio, Inc. (NYSE: IBIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- iBio, Inc. (NYSE: IBIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- iBio, Inc. (NYSE: IBIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CNN values your feedback [CNN]CNN
- iBio, Inc. (NYSE: IBIO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
IBIO
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 424B3
- 4/25/24 - Form EFFECT
- IBIO's page on the SEC website